发明名称 |
TARGETING PARP1 FOR TREATMENT OF TSC AND CANCERS |
摘要 |
The present invention relates to methods of treating a condition associated with mTORC1 hyperactivation or TSC2-deficient cancer, the method comprising administering to a subject having the cancer a pharmaceutically-effective amount of a poly(ADP-ribose) polymerase 1 (PARP1) inhibitor. In some embodiments, the condition associated with mTORC1 hyperactivation is tuberous sclerosis complex (TSC). In some embodiments, the condition associated with mTORC1 hyperactivation is lymphangioleiomyomatosis (LAM). In some embodiments, the condition associated with mTORC1 hyperactivation is TSC2-deficient cancer. |
申请公布号 |
WO2015164586(A1) |
申请公布日期 |
2015.10.29 |
申请号 |
WO2015US27264 |
申请日期 |
2015.04.23 |
申请人 |
THE BRIGHAM AND WOMEN'S HOSPITAL, INC.;LEE, PO-SHUN |
发明人 |
LEE, PO-SHUN;YU, JANE;SUN, YANG |
分类号 |
A61K48/00;A61K38/00;C12P19/34 |
主分类号 |
A61K48/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|